Role Of Integrins In Insulin Signaling

Abstract

Researchers at the University of California, Davis have developed single-chain insulin (SCI) technology, an insulin-based therapeutic approach that may improve treatment for diabetes and cancer by combining insulin, IGF, and integrin signaling properties.

Full Description

This technology involves isolated proteins and vectors encoding single-chain insulin analogs where insulin’s A and B chains are linked via an integrin-binding domain from IGF1 or IGF2, either wild-type or mutated. The SCI acts either as an antagonist or agonist of the insulin receptor, enabling dual therapeutic functionality: suppressing cancer cell proliferation or improving insulin sensitivity and glucose uptake. The SCI’s design addresses current insulin therapy limitations by enhancing stability, reducing cold-chain dependencies, and targeting integrin-mediated signaling pathways relevant to metabolic disorders and malignancies.

Applications

• Diabetes treatment, including type 1, type 2, and associated metabolic syndromes. 
• Cancer therapeutics targeting breast cancer, prostate cancer, melanoma, and other malignancies. 
• Development of novel insulin analog therapies with enhanced stability and efficacy. 
• Biopharmaceutical production of integrin-targeting single-chain insulin proteins and gene therapy vectors. 
• Combination therapies co-administered with existing glucose-lowering drugs. 
• Research tools for studying insulin, IGF, and integrin signaling in metabolic and cancer biology.

Features/Benefits

• Improves stability and relaxes storage requirements versus traditional insulin, reducing reliance on strict cold-chain handling. 
• Delivers dual therapeutic activity by suppressing cancer-related signaling while improving insulin sensitivity. 
• Modulates receptor signaling through an integrin-binding linker domain, enabling targeted control of pathway cross-talk. 
• Enables tunable insulin receptor behavior by switching between agonist or antagonist activity via specific linker mutations. 
• Reduces treatment cost and operational complexity by simplifying storage, distribution, and overall therapy logistics. 
• Supports combination therapy by remaining compatible with established glucose-lowering agents (e.g., metformin, GLP‑1 receptor agonists). 
• Expands administration options by supporting both gene-delivery (vector-based expression) and protein formulation delivery approaches. 
• Eliminates cold-chain-driven storage and distribution burdens that increase insulin cost and logistical complexity. 
• Addresses the lack of more stable, higher-performing insulin analog options by improving durability and usability. 
• Fills the gap for therapies that jointly target diabetes and cancer by leveraging insulin and integrin pathway mechanisms. 
• Provides a needed insulin receptor antagonist approach for cancer therapy, where such options are currently limited. 
• Exploits previously underused insulin/IGF/integrin signaling interplay by translating complex pathway cross-talk into a therapeutic strategy.

Patent Status

Patent Pending